1h Free Analyst Time
The publisher has been monitoring the pruritus drugs market and it is poised to grow by $ 6.87 bn during 2022-2026, progressing at a CAGR of 8.06% during the forecast period. This report on the pruritus drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing preference for immunotherapy, rising prevalence of chronic diseases, and increasing awareness and rising use of therapeutics.
The pruritus drugs market analysis includes the application segment and geographic landscape.
The pruritus drugs market is segmented as below:
By Application
- Hematologic pruritus
- Oncological pruritus
- Renal pruritus
- Endocrine pruritus
- Cholestatic pruritus
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW
This study identifies the emergence of novel treatment options as one of the prime reasons driving the pruritus drugs market growth during the next few years. Also, nanoparticle-enabled transdermal drug delivery systems and increasing research funding will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
This report on pruritus drugs market covers the following areas:
- Pruritus drugs market sizing
- Pruritus drugs market forecast
- Pruritus drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pruritus drugs market vendors that include AbbVie Inc., Almirall SA, Astellas Pharma Inc., Bristol-Myers Squibb Co., Cara Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Cipla Ltd., GlaxoSmithKline Plc, and Lupin Ltd. Also, the pruritus drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The Publisher Announces the Publication of its Research Report - Global Pruritus Drugs Market 2022-2026The publisher recognizes the following companies as the key players in the global pruritus drugs market: AbbVie Inc., Almirall SA, Astellas Pharma Inc., Bristol-Myers Squibb Co., Cara Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Cipla Ltd., GlaxoSmithKline Plc, and Lupin Ltd.
Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is emergence of novel treatment options.'
According to the report, one of the major drivers for this market is the growing preference for immunotherapy.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Almirall SA
- Astellas Pharma Inc.
- Bristol-Myers Squibb Co.
- Cara Therapeutics Inc.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Ipca Laboratories Ltd.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Roivant Sciences Ltd.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- GlaxoSmithKline Plc
- Lupin Ltd.
